From the Journals

Ethosuximide vs Placebo for IBS Pain

Randomized trial found no improvement in abdominal pain and higher discontinuation rates with the calcium channel blocker.

Share

  • 1

    Ethosuximide did not improve abdominal pain in IBS patients compared to placebo.

  • 2

    The study involved 124 participants over 12 weeks.

  • 3

    27% of ethosuximide patients met responder criteria, against 23% for placebo.

  • 4

    Higher discontinuation due to adverse events in ethosuximide group (47% vs 22%).

  • 5

    Common adverse events: headache, fatigue, nausea, dizziness.

  • 6

    No significant differences in secondary endpoints between groups.

  • 7

    Further research is needed on safer calcium channel modulators.

Original Source(s)

Ethosuximide vs Placebo for IBS Pain

Randomized trial found no improvement in abdominal pain and higher discontinuation rates with the calcium channel blocker.

  • by Olivia Anderson

  • February 20, 2026

  • 3 min

Related Content

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

Proton Pump Inhibitors and Cancer Risk

Investigators evaluate cancer risk tied to extended acid suppression therapy.

Appendicitis Care: A Decade Later

Antibiotics remain viable option for uncomplicated appendicitis in adult patients at ten years